MedMira Inc 47M
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CAD 0.05
- Day Range
- CAD 0.05–0.05
- 52-Week Range
- —–0.58
- Bid/Ask
- CAD 0.00 / CAD 0.00
- Market Cap
- CAD 34.38 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 122.73
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.medmira.com
Comparables
Valuation
|
Metric
|
47M
|
DIA
|
BNGO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 19.95 | — |
Price/Book Value | — | 3.30 | 0.58 |
Price/Sales | 122.73 | 4.75 | 0.88 |
Price/Cash Flow | — | 15.82 | — |
Price/Earnings
47M
DIA
BNGO
Financial Strength
|
Metric
|
47M
|
DIA
|
BNGO
|
|---|---|---|---|
Quick Ratio | 0.13 | — | 1.04 |
Current Ratio | 0.15 | — | 1.46 |
Interest Coverage | −1.82 | 11.71 | −43.61 |
Quick Ratio
47M
DIA
BNGO
Profitability
|
Metric
|
47M
|
DIA
|
BNGO
|
|---|---|---|---|
Return on Assets (Normalized) | −72.17% | — | −59.94% |
Return on Equity (Normalized) | — | 11.76% | −90.03% |
Return on Invested Capital (Normalized) | — | 10.85% | −74.32% |
Return on Assets
47M
DIA
BNGO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Wxvkxkjrt | Hpfnc | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fsqxbfc | Yyywxq | $114.2 Bil | |||
| Moderna Inc
MRNA
| Wsgjnvyh | Wqhjd | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Vltdtxdln | Rfg | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ddvxrbyx | Crhm | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fhnwsbq | Yccmrh | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xklgcjqf | Shpbqz | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Pjrwkwpgz | Dlqx | $12.8 Bil | |||
| Incyte Corp
INCY
| Mwvzshtjl | Hybfrj | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Ysrypdzngx | Hpghg | $12.2 Bil |